Time response of carboplatin-induced nephrotoxicity in rats

Pharmacological Research

Volumn 50, Issue 3, 2004, Pages 291-300

  Husain, Kazim ^a,b   Whitworth, Craig ^a   Rybak, Leonard P ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PONCE SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Anti oxidants; Carboplatin; Nephrotoxicity; Rat; Time response

Indexed keywords

CARBOPLATIN; CATALASE; COPPER; CREATININE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; LIPID; MANGANESE SUPEROXIDE DISMUTASE; NITROGEN; PLATINUM; SUPEROXIDE DISMUTASE; UREA; ZINC;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GLUTATHIONE METABOLISM; ISOLATED KIDNEY; KIDNEY PARENCHYMA; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; TISSUE LEVEL; TOXICOKINETICS; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BLOOD UREA NITROGEN; CARBOPLATIN; KIDNEY; LIPID PEROXIDATION; MALE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 3042680947     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2004.04.001     Document Type: Article

References (47)

1. Fujiwara K., Sakuragi N., Suzuki S., Yoshida N., Maehata K., Nishiya M., et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long term follow up. Gynecol. Oncol. 90:2003;637-643
2. Pivot X., Cals L., Cupissol D., Guardiola E., Tchiknavorian X., Guerrier P., et al. Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of head and neck. Oncology. 60:2001;66-71
3. Ettinger D.S. The role of carboplatin in the treatment of small-cell lung cancer. Oncology. 12:1998;36-43
4. Alberts D.S. Carboplatin versus cisplatin in ovarian cancer. Semin. Oncol. 22:1995;88-90
5. Mckeage M.J. Comparative adverse effect profiles of platinum drugs. Drug Saf. 13:1995;228-244
6. Meyer W.H., Pratt C.B., Paquette C.A., Rao B.N., Pradhan D.M., Marina N.M., et al. Carboplatin/ifosfomide window therapy for osteosarcoma: results of the St. Jude Children's Hospital OS-91 trial. J. Clin. Oncol. 19:2001;171-182
7. Los G., Van Vugt M.J.H., Engelse L.D., Pinedo H.M. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem. Pharmacol. 46:1993;1229-1237
8. English M.W., Skinner R., Pearson A.D.J., Price L., Wyllie R., Craft A.W. Dose-related nephrotoxicity of carboplatin in children. Br. J. Cancer. 81:1999;336-341
9. Bohm S., Oriana S., Spatti G., Di Re F., Breasciani G., Pirovano C., et al. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. Oncology. 57:1999;115-120
10. Wandt H., Birkmann J., Denzel T., Schafer K., Schwab G., Pilz D., et al. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant. 23:1999;763-770
11. Cavaletti G., Bagliun G., Zincone A., Marzorati L., Melzi P., Frattola L., et al. Neuro and ototoxicity of high dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res. 18:1998;3797-3802
12. Husain K., Scott R.B., Whitworth C., Somani S.M., Rybak L.P. Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system. Hear. Res. 151:2001;71-78
13. Yasumasu T., Ueda T., Uozumi J., Mihara Y., Kumazawa J. Comparative study of cisplatin and carboplatin on pharmacokinetics, nephrotoxicity and effect on renal nuclear DNA synthesis in rats. Pharmacol. Toxicol. 70:1992;143-147
14. Agraharkar M., Nerenstone S., Palmisano J., Kaplan A.A. Carboplatin-related hematuria and acute renal failure. Am. J. Kidney Dis. 32:1998;1-4
15. Poirier M.C., Reed E., Litterst C.L., Katz D., Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res. 52:1992;149-153
16. Blommaert F.A., Michael C., Van Dijk-Knijnenburg H.C., Schornagel J.H., de Engelse L., Fichtinger-Schepman A.M. The formation of persistence of carboplatin-DNA adducts in rat. Cancer Chemother. Pharmacol. 38:1996;273-280
17. Husain K., Jagannathan R., Hasan Z., Trammell G.L., Rybak L.P., Hazelrigg S.R., et al. Dose response of carboplatin-induced nephrotoxicity in rat. Pharmacol. Toxicol. 91:2002;83-89
18. Litterst C.L., Schweitzer V.G. Covalent binding of platinum to renal protein from sensitive and resistant guinea pigs treated with cisplatin: possible role in nephrotoxicity. Res. Commun. Chem. Pathol. Pharmacol. 61:1988;35-48
19. Misra H.P., Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide-dismutase. J. Biol. Chem. 247:1972;3170-3175
20. Aebi H. Catalase in vitro. Meth. Enzymol. 105:1984;121-126
21. Flohe L., Gunzler W. Assays of glutathione peroxidase. Meth. Enzymol. 105:1984;114-121
22. Carlberg I., Mannervik B. Glutathione reductase. Meth. Enzymol. 113:1995;484-490
23. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione-S-transferases. The first step in mercapturic acid formation. J. Biol. Chem. 249:1974;7130-7139
24. Singh N.M., Bogavac L., Kalimanovska V., Jelic Z., Spasic S. Spectrophotometric assay of xanthine oxidase with 2, 2′-azino-di(3- ethylbenzthiazoline-6-sulphonate) (ABTS) as chromogen. Clin. Chem. Acta. 162:1987;29-36
25. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animals and tissues by thiobarbituric acid reaction. Anal. Biochem. 95:1979;351-358
26. Read S.M., Northcole D.H. Minimization of variation in the response to different protein of the Coomassie blue G dye-binding assay for protein. Anal. Biochem. 116:1981;53-64
27. Bishop J.F. Current experience with high dose carboplatin therapy. Semin. Oncol. 19:1992;150-154
28. Maldoon L.L., Pagel M.A., Kroll R.A., Brummett R.E., Doolittle N.D., Zuhowski E.G., et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin. Cancer Res. 6:2000;309-315
29. Ueda T., Yasumasu T., Uozumi J. Experimental studies on pharmacokinetics and nephrotoxicity of carboplatin in rats. J. Toxicol. Sci. 16:1991;101-109
30. Martinez F., Deray G., Dubois M., Beaufile H., Jacquiaud C., Bourbouze R., et al. Comparative nephrotoxicity of carboplatin and cisplatin in euvolemic and dehydrated rats. Anticancer Drugs. 4:1993;85-90
31. Dube S.N., Husain K., Sugendran K., Vijayaraghavan R., Somani S.M. Dose response of sulphur mustard: behavioral and toxic signs in rats. Ind. J. Physiol. Pharmacol. 42:1998;389-394
32. Husain K., Morris C., Whitworth C., Trammel G.L., Rybak L.P., Somani S.M. Protection by ebselen against cisplatin induced nephrotoxicity: antioxidant system. Mol. Cell. Biochem. 178:1998;127-133
33. Wolfgang G.H., Dominick M.A., Walsh K.M., Hoeschele J.D., Pegg D.G. Comparative nephrotoxicity of a novel platinum compounds, cisplatin and carboplatin in male Wistar rats. Fundam. Appl. Toxicol. 22:1994;73-79
34. Boisdron-Celle M., Lebouil A., Allain P., Gamelin E. Pharmacokinetic properties of platinum derivatives. Bull. Cancer. 88:2001;14-19
35. Werner P., Cohen G. Glutathione disulfide (GSSG) as a marker of oxidative injury to brain mitochondria. Ann. N. Y. Acad. Sci. 679:1993;364-369
36. Deleve S.M., Kaplowitz N. Importance and regulation of hepatic glutathione. Sami. Liv. Dis. 10:1990;251-256
37. Younes M., Siegers C.P. Mechanistic aspects of enhanced lipid peroxidation following glutathione depletion in vivo. Chem. Biol. Interact. 34:1981;257-266
38. Hu B.H., McFadden S.L., Salvi R.J., Henderson D. Intracochlear infusion of buthionine sulfoximine potentiates carboplatin ototoxicity in the chinchilla. Hear. Res. 128:1999;125-134
39. Babu E., Gopal Krishnan V.K., Sriganth I.N.P., Gopal Krishnan R., Sakthisekaran D. Cisplatin-induced nephrotoxicity and the modulating effect of glutathione ester. Mol. Cell. Biochem. 144:1995;7-11
40. Hamers F.P.T., Brakkee J.H., Cavalletti E., Tedeschi M., Marmonti L., Pezzoni G., et al. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res. 53:1993;544-549
41. Fontanelli R., Spatti G., Raspagliesi F., Zunino F., Di Re F. A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann. Oncol. 3:1992;117-121
42. Hannemann J., Baumann K. Nephrotoxicity of cisplatin, carboplatin and transplatin - a comparative in vitro study. Arch. Toxicol. 764:1990;393-400
43. Husain K., Somani S.M. Effect of exercise training and chronic ethanol ingestion on cholinesterase activity and lipid peroxidation in blood and brain regions of rat. Prog. Neuro-Psychopharmacol. Biol. Psychiatr. 22:1998;411-423
44. Marklund S.L. Regulation of cytokines of extracellular superoxide dismutase and other superoxide dismutase isozyme in fibroblasts. J. Biol. Chem. 267:1992;6696-6701
45. Boulikas T., Vougiouka M. Cisplatin and platinum drugs at the molecular level (review). Oncol. Rep. 10:2003;1663-1682
46. Clerici W.J., Hensley K., DiMartino D.L., Butterfield D.A. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear. Res. 98:1996;116-124
47. Matsuda H., Tanaka T., Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem. Biophys. Res. Commun. 203:1994;1175-1180